Efavirenz is a non-nucleoside reverse transcriptase inhibitor that can be added to tenofovir and lamivudine as first-line antiretroviral therapy.

In patients taking efavirenz, 0.14 % may develop Stevens–Johnson syndrome.

Here, a patient with human immunodeficiency virus developed Stevens–Johnson syndrome 2 weeks after the introduction of efavirenz (600 mg once daily).